Skip to main content
. 2004;6(Suppl 9):S46–S52.

Table 1.

Treatment Options for Patients With Moderate to Severe Symptom of Benign Prostatic Hyperplasia

Watchful waiting
Medical therapies

  • α-Adrenergic blockers

  • Alfuzosin

  • Doxazosin

  • Tamsulosin

  • Terazosin

  • 5α-Reductase inhibitors

  • Dutasteride*

  • Finasteride

  • Combination therapy (α-blocker and 5α-reductase inhibitor)*;,†

Minimally invasive therapies

  • Transurethral microwave heat treatments

  • CoreTherm™*

  • Prostatron® (various versions)

  • Targis®

  • TherMatrx®*

  • Transurethral needle ablation

  • UroLume® stent‡

Surgical therapies

  • Transurethral resection of the prostate

  • Transurethral electrovaporization

  • Transurethral incision of the prostate

  • Transurethral holmium laser resection/enucleation

  • Transurethral laser vaporization

  • Transurethral laser coagulation (eg, visual laser ablation)

  • Open prostatectomy

*

Recommendations based on randomized, controlled trials not included in the outcomes tables.

†

The panel assumes that the combination of any effective α-blocker and 5α-reductase inhibitor probably produces a comparable benefit. However, the best-tested combination is doxazosin and finasteride. The safety of specific combinations other than finasteride plus doxazosin, terazosin, and alfuzosin has not been assessed.

‡

Not for patients with poor surgical risk.

Reproduced with permission from American Urological Association Education and Research, Inc.9